BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26489674)

  • 41. Elevated expression of ECT2 predicts unfavorable prognosis in patients with colorectal cancer.
    Luo Y; Qin SL; Mu YF; Wang ZS; Zhong M; Bian ZQ
    Biomed Pharmacother; 2015 Jul; 73():135-9. PubMed ID: 26211594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas.
    Han SL; Wu XL; Wan L; Zeng QQ; Li JL; Liu Z
    Dig Surg; 2009; 26(2):156-62. PubMed ID: 19365123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stroma derived COL6A3 is a potential prognosis marker of colorectal carcinoma revealed by quantitative proteomics.
    Qiao J; Fang CY; Chen SX; Wang XQ; Cui SJ; Liu XH; Jiang YH; Wang J; Zhang Y; Yang PY; Liu F
    Oncotarget; 2015 Oct; 6(30):29929-46. PubMed ID: 26338966
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center.
    Katna R; Shet T; Sengar M; Menon H; Laskar S; Prabhash K; D'Cruz A; Nair R
    Head Neck; 2013 Feb; 35(2):165-71. PubMed ID: 22368156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer.
    Ma F; Bi L; Yang G; Zhang M; Liu C; Zhao Y; Wang Y; Wang J; Bai Y; Zhang Y
    Oncol Rep; 2014 Sep; 32(3):1071-7. PubMed ID: 25017610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer.
    De Silva P; Garaud S; Solinas C; de Wind A; Van den Eyden G; Jose V; Gu-Trantien C; Migliori E; Boisson A; Naveaux C; Duvillier H; Craciun L; Larsimont D; Piccart-Gebhart M; Willard-Gallo K
    EBioMedicine; 2019 Jan; 39():226-238. PubMed ID: 30579865
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel epigenetic regulation of circFoxp1 on Foxp1 in colon cancer cells.
    Luo Y; Liu F; Ma J; Fu Y; Gui R
    Cell Death Dis; 2020 Sep; 11(9):782. PubMed ID: 32951006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement.
    Barrans SL; Fenton JA; Ventura R; Smith A; Banham AH; Jack AS
    Haematologica; 2007 Jun; 92(6):863-4. PubMed ID: 17550867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene Expression Profiling of Head and Neck Tumors Identifies FOXP1 and SOX10 Expression as Useful for Distinguishing Ameloblastoma From Basaloid Salivary Gland Tumors.
    Ko YCK; Varma S; Zhu CF; Zhu SX; Vennam S; Poh CF; Jordan RC; Kong C; Pollack JR; West RB
    Am J Surg Pathol; 2020 May; 44(5):665-672. PubMed ID: 31895100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemical expression analysis of leucine-rich PPR-motif-containing protein (LRPPRC), a candidate colorectal cancer biomarker identified by shotgun proteomics using iTRAQ.
    Nishio T; Kurabe N; Goto-Inoue N; Nakamura T; Sugimura H; Setou M; Maekawa M
    Clin Chim Acta; 2017 Aug; 471():276-282. PubMed ID: 28622966
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells.
    Oskay Halacli S
    Cell Biol Int; 2017 Jan; 41(1):102-110. PubMed ID: 27859969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss of RNA-binding motif protein 3 expression is associated with right-sided localization and poor prognosis in colorectal cancer.
    Melling N; Simon R; Mirlacher M; Izbicki JR; Stahl P; Terracciano LM; Bokemeyer C; Sauter G; Marx AH
    Histopathology; 2016 Jan; 68(2):191-8. PubMed ID: 25922889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The high expression of FOXE1 in colorectal cancer predicts a promising prognosis: a retrospective study.
    Liu X; Chen L; Wen F; Zheng S; Ge W
    Clin Exp Med; 2023 Nov; 23(7):3995-4001. PubMed ID: 37278933
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients.
    Pallante P; Terracciano L; Carafa V; Schneider S; Zlobec I; Lugli A; Bianco M; Ferraro A; Sacchetti S; Troncone G; Fusco A; Tornillo L
    Eur J Cancer; 2010 Aug; 46(12):2304-13. PubMed ID: 20542683
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FoxP1 orchestration of ASD-relevant signaling pathways in the striatum.
    Araujo DJ; Anderson AG; Berto S; Runnels W; Harper M; Ammanuel S; Rieger MA; Huang HC; Rajkovich K; Loerwald KW; Dekker JD; Tucker HO; Dougherty JD; Gibson JR; Konopka G
    Genes Dev; 2015 Oct; 29(20):2081-96. PubMed ID: 26494785
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Whole genome sequencing identifies a de novo 2.1 Mb balanced paracentric inversion disrupting FOXP1 and leading to severe intellectual disability.
    Vuillaume ML; Cogné B; Jeanne M; Boland A; Ung DC; Quinquis D; Besnard T; Deleuze JF; Redon R; Bézieau S; Laumonnier F; Toutain A
    Clin Chim Acta; 2018 Oct; 485():218-223. PubMed ID: 29969624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gastrointestinal dysfunction in autism displayed by altered motility and achalasia in
    Fröhlich H; Kollmeyer ML; Linz VC; Stuhlinger M; Groneberg D; Reigl A; Zizer E; Friebe A; Niesler B; Rappold G
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22237-22245. PubMed ID: 31611379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FOXP1 inhibits pancreatic cancer growth by transcriptionally regulating IRF1 expression.
    Wang L; Luo P; Yang Z; Zhong X; Ji C
    PLoS One; 2023; 18(3):e0280794. PubMed ID: 36952469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role.
    Bullock MD; Bruce A; Sreekumar R; Curtis N; Cheung T; Reading I; Primrose JN; Ottensmeier C; Packham GK; Thomas G; Mirnezami AH
    Br J Cancer; 2013 Jul; 109(2):387-94. PubMed ID: 23828518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.